Announced pivotal topline data from Phase I/II study of AMT-130 in Huntington’s disease met its primary and key secondary endpoints, ...
CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today ...
Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the 'Company”) today announced financial results for the third quarter ended September 30, 2025, and provided a business update.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback